RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange that Credit Analysis & Research Limited (CARE), has revised credit rating for long term debt instruments issued by the Company, from CARE AA+ (DoubIe A Plus) to CARE AA (Double A). Long term Instruments with CARE AA rating are considered to have high degree of safety regarding timely payment of financial obligations and carry very low credit risk.However, CARE has reaffirmed the CARE A1+(A One Plus) rating assigned to the short term bank facilities of the Company. Short Term Debt Instruments with CARE rating of A1+ are considered to have v

Ranbaxy Laboratories Limited has informed the Exchange that ICRA has assigned the rating of "[ICRA] A1+" (pronounced as A One Plus) to the Company's Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs.800 crores.

Ranbaxy Laboratories Limited has informed the Exchange that ICRA has assigned the rating of "[ICRA]A1+" (pronounced as A One Plus) to the Company's Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs. 800 Crores. Earlier CP/STD programme of the Company for Rs.1200 Crores was also assigned the same rating i.e. "[ICRA]A1+" . Instruments with "[ICRA]A1+" rating are considered to have very strong degree of safety regarding timely payment of financial obligations. Such instruments carry lowest credit risk.